ClinicalTrials.gg

Program

dostarlimab

Also written as “Dostarlimab”, “TSR-042” and “Dostarlimab (TSR-042)”.

Its studies are mostly in Ovarian Neoplasms · Endometrial Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 2 companies.

Furthest: phase 4, since Mar 20, 202526 company-led studies, 17 open or runningNext primary completion: Nov 23, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline2517 open or runningphase 4since Mar 20, 2025Mar 9, 2016Nov 23, 2026phase 2 · NCT06567782
AGO Research10 open or runningphase 2since Oct 18, 2021Oct 18, 2021none ahead

Also a collaborator on its studies: iteos-therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Mar 9, 2016.

  1. Feb 2, 20232 phase 2 studiesGlaxoSmithKline · NCT05723562, NCT05751629
  2. May 3, 2023Phase 3 study in Colonic NeoplasmsGlaxoSmithKline · NCT05855200 · 892 planned · United States, Argentina, Australia and more
  3. Feb 5, 2024Phase 3 study in Head and Neck NeoplasmsGlaxoSmithKline · NCT06256588 · 864 planned · United States, Argentina, Australia and more
  4. Mar 12, 2024Phase 2 study in CarcinomaGlaxoSmithKline · NCT06317311 · 41 enrolled · Japan
  5. Jun 18, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungGlaxoSmithKline · NCT06472076 · 88 enrolled · United States, Argentina, Belgium and more
  6. Aug 20, 2024Phase 2 study in Colonic NeoplasmsGlaxoSmithKline · NCT06567782 · 120 planned · Belgium, Italy, Japan and more
  7. Oct 10, 20242 phase 2 studiesGlaxoSmithKline · NCT06640049, NCT06655818
  8. Mar 20, 2025Phase 4 study in Endometrial NeoplasmsGlaxoSmithKline · NCT06897527 · 100 planned
  9. Aug 5, 2025Phase 2 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07108270 · 30 planned · China
  10. Jun 11, 2026Phase 4 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07652515 · 100 planned
  11. Jul 24, 2026Phase 3 study in Rectal NeoplasmsGlaxoSmithKline · NCT07740720 · 100 planned · Japan
  12. Sep 30, 2026Phase 3 study in Endometrial NeoplasmsGlaxoSmithKline · NCT07860450 · 378 planned
  13. Nov 2, 2026Primary completion moved from 2026-07-15 to 2026-12-14Date moved laterphase 2 · +5 months · NCT06317311
  14. Nov 16, 2026Primary completion moved from 2029-12-12 to 2030-03-13Date moved laterphase 3 · +3 months · NCT07740720

Ahead

  1. Nov 2, 2026Primary completion: phase 2 study in Rectal NeoplasmsGlaxoSmithKline · NCT05723562
  2. Nov 23, 2026Primary completion: phase 2 study in Colonic NeoplasmsGlaxoSmithKline · NCT06567782
  3. Nov 26, 2026Primary completion: phase 3 study in NeoplasmsGlaxoSmithKline · NCT03981796
  4. Dec 14, 2026Primary completion: phase 2 study in CarcinomaGlaxoSmithKline · NCT06317311

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07860450Endometrial Neoplasms3Not yet recruitingGlaxoSmithKlineNov 5, 2030378
NCT07740720Rectal Neoplasms · Japan3Not yet recruitingGlaxoSmithKlineMar 13, 2030100
NCT07652515Endometrial Neoplasms4Not yet recruitingGlaxoSmithKlineAug 30, 2030100
NCT07108270Endometrial Neoplasms · China2RecruitingGlaxoSmithKlineMar 31, 203030
NCT06897527Endometrial Neoplasms4Not yet recruitingGlaxoSmithKlineJan 13, 2027100
NCT06655818Multiple Myeloma · France, Korea, Republic of2TerminatedGlaxoSmithKlineFeb 14, 20244
NCT06640049Rectal Neoplasms · China2Active, not recruitingGlaxoSmithKlineOct 24, 202723
NCT06567782Colonic Neoplasms · Belgium, Italy, Japan and more2RecruitingGlaxoSmithKlineNov 23, 2026120
NCT06472076Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more3Active, not recruitingGlaxoSmithKlineJun 30, 202688
NCT06317311Carcinoma · Japan2Active, not recruitingGlaxoSmithKlineDec 14, 202641
NCT06256588Head and Neck Neoplasms · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineJun 30, 2028864
NCT05855200Colonic Neoplasms · United States, Argentina, Australia and more3RecruitingGlaxoSmithKlineMar 19, 2029892
NCT05751629Ovarian Neoplasms · United States2CompletedGlaxoSmithKlineApr 1, 202241
NCT05723562Rectal Neoplasms · United States, Canada, France and more2Active, not recruitingGlaxoSmithKlineNov 2, 2026154
NCT05126342Ovarian Neoplasms2WithdrawnAGO ResearchNov 1, 20240
NCT04655976Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingGlaxoSmithKlineJun 5, 2025758
NCT04544995Neoplasms · United Kingdom1TerminatedGlaxoSmithKlineApr 23, 202547
NCT04581824Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more2TerminatedGlaxoSmithKlineAug 4, 2022243
NCT04126200Multiple Myeloma · United States, Brazil, Canada and more2Active, not recruitingGlaxoSmithKlineApr 17, 2025208
NCT03981796Neoplasms · United States, Belarus, Belgium and more3Active, not recruitingGlaxoSmithKlineNov 26, 2026785
NCT03955471Ovarian Neoplasms · United States2TerminatedGlaxoSmithKlineAug 18, 202141
NCT03602859Ovarian Neoplasms · United States, Belarus, Belgium and more3Active, not recruitingGlaxoSmithKlineOct 31, 20241,400
NCT03574779Ovarian Neoplasms · United States, Canada, Spain2CompletedGlaxoSmithKlineJun 28, 202477
NCT03308942Neoplasms · United States2CompletedGlaxoSmithKlineMay 4, 202053
NCT03307785Neoplasms · United States1CompletedGlaxoSmithKlineFeb 26, 202060
NCT02715284Neoplasms · United States, Argentina, Brazil and more1Active, not recruitingGlaxoSmithKlineMay 18, 2026729

How it is read

Names in the registry

  • “Dostarlimab”, 22 entries
  • “TSR-042”, 2 entries
  • “Dostarlimab (TSR-042)”, 1 entry
  • “TSR-042 (Dostarlimab)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.